Celldex Therapeutics (CLDX) EBIT Margin (2010 - 2026)
Celldex Therapeutics' (CLDX) quarterly EBIT Margin came in at 562900.0% in Q1 2026, down 55387281.0% year-on-year from N/an in Q1 2025, and down 681.51% quarter-over-quarter from 72027.27% in Q4 2025.
Celldex Therapeutics (CLDX) EBIT Margin (2010 - 2026) Analysis & Trends
Celldex Therapeutics' EBIT Margin history runs 17 years deep, the most recent figure standing at 562900.0% for Q1 2026.
- On a quarterly basis, EBIT Margin fell 55387281.0% year-over-year to 562900.0% in Q1 2026; TTM through Mar 2026 was 35688.45%, a 3281494.0% decrease from a year earlier, with the FY2025 full-year figure at 18599.81%, down 1582092.0% from the prior year.
- EBIT Margin declined to 562900.0% in Q1 2026 per CLDX's latest filing, from 72027.27% in the prior quarter.
- Across five years, EBIT Margin topped out at 1152.92% in Q4 2023 and bottomed at 562900.0% in Q1 2026.
- The 5-year median for EBIT Margin is 7776.22% (2022), against an average of 46927.28%.
- Across the five-year window, EBIT Margin jumped 1700357 bps in 2025 and sank 55387281 bps in 2026, its largest moves.
- Year by year, EBIT Margin stood at 1728.77% in 2022, then jumped by 33 bps to 1152.92% in 2023, then sank by 314 bps to 4768.26% in 2024, then sank by 1411 bps to 72027.27% in 2025, then plunged by 682 bps to 562900.0% in 2026.
- Per Business Quant, the three latest CLDX EBIT Margin figures stand at 562900.0% (Q1 2026), 72027.27% (Q4 2025), and 8747.53% (Q2 2025).
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBIT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 16.51% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 38.10% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 17.83% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 31.68% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Celldex Therapeutics | 1.72 Mn | 1.72 Mn | -1.44 Mn | -562,900.00% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -562,900.00% |
| Dec 31, 2025 | -72,027.27% |
| Jun 30, 2025 | -8,747.53% |
| Mar 31, 2025 | -9,027.19% |
| Dec 31, 2024 | -4,768.26% |
| Sep 30, 2024 | -1,633.53% |
| Jun 30, 2024 | -1,854.16% |
| Mar 31, 2024 | -26,030.77% |
| Dec 31, 2023 | -1,152.92% |
| Sep 30, 2023 | -2,718.46% |
| Jun 30, 2023 | -12,389.93% |
| Mar 31, 2023 | -3,357.91% |
| Dec 31, 2022 | -1,728.77% |
| Sep 30, 2022 | -6,804.91% |
| Jun 30, 2022 | -22,328.83% |
| Mar 31, 2022 | -13,366.09% |
| Dec 31, 2021 | -6,089.82% |
| Sep 30, 2021 | -13,610.46% |
| Jun 30, 2021 | -386.21% |
| Mar 31, 2021 | -2,429.05% |